Cyclopharm names sole $5m investor in Tranche 2 placement

Cyclopharm Limited ( (AU:CYC) ) has issued an announcement.

Cyclopharm Limited has clarified that Barings Acceptance Limited will be the sole participant in Tranche 2 of its previously announced placement, contributing $5 million in subscription funds. Barings Acceptance, already a substantial shareholder with about 9.95% of Cyclopharm’s issued capital, is confirmed as independent from related parties, key management, other substantial holders, and company advisers.

The company said all other details of its Annual General Meeting notice, including the proxy form and any proxies already lodged, remain unchanged and valid for all resolutions. The update provides shareholders with greater transparency on the placement’s investor composition ahead of the AGM, underscoring that the capital raise does not alter governance or voting procedures already in place.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.50 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an ASX-listed radiopharmaceutical company that services the global medical community. Its core product is Technegas, used for functional lung ventilation imaging, supporting nuclear medicine and other clinicians in improving patient care outcomes.

Average Trading Volume: 145,437

Technical Sentiment Signal: Sell

Current Market Cap: A$93.62M

For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.